铁死亡抑制蛋白1在肝脏疾病中的作用机制及潜在治疗靶点  

Mechanism of action and potential therapeutic targets of ferroptosis suppressor protein 1 in liver diseases

作　　者：王思思 王亚茹 刘睿[1] 秦洁[1] WANG Sisi;WANG Yaru;LIU Rui;QIN Jie(Department of Endocrinology,Shanxi Provincial People’s Hospital,Shanxi Medical University,Taiyuan 030012,China)

机构地区：[1]山西医科大学附属山西省人民医院内分泌科,太原030012

出　　处：《临床肝胆病杂志》2024年第7期1493-1497,共5页Journal of Clinical Hepatology

基　　金：山西省自然科学研究面上项目(202203021211059)。

摘　　要：铁死亡抑制蛋白1(FSP1)是最近发现除谷胱甘肽过氧化酶4之外的另一个主要的铁死亡调节因子,能够清除细胞内的活性氧和脂质自由基,抑制铁死亡的发生。鉴于肝脏在铁和脂质代谢中的关键作用及其对氧化损伤的易感性,越来越多的证据表明FSP1在代谢相关脂肪性肝病、肝细胞癌、急性肝衰竭、酒精性肝损伤等肝脏疾病中发挥重要作用,FSP1相关靶点有望成为一种潜在的治疗选择。本文旨在对FSP1进行全面综述,重点总结FSP1在几种常见肝病的病理生理学中的作用,强调其作为肝脏疾病靶点的潜力,为肝脏疾病的治疗提供新思路。Ferroptosis suppressor protein 1(FSP1)is another major ferroptosis regulator besides glutathione peroxidase 4,which can scavenge intracellular reactive oxygen species and lipid peroxides and inhibit ferroptosis.In view of the key role of the liver in iron and lipid metabolism and its susceptibility to oxidative damage,more and more evidence has shown that FSP1 plays an important role in liver diseases such as metabolic associated fatty liver disease,hepatocellular carcinoma,acute liver failure,and alcoholic liver disease,and the related targets of FSP1 are expected to become a potential treatment option.This article comprehensively reviews FSP1,with a focus on the role of FSP1 in the pathophysiology of several common liver diseases and the potential of FSP1 as a target of liver diseases,in order to provide new ideas for the treatment of liver diseases.

关 键 词：肝疾病 抑制蛋白类 铁死亡 

分 类 号：R575[医药卫生—消化系统]